Interim analysis of cytarabine (ara-C) and cladribine (2-CDA) combination therapy in acute myeloid leukemia (AML).

被引：0
|
作者：
Radomski, KM
Gandhi, V
Srivastava, DK
Razzouk, BI
Behm, FG
Plunkett, W
Pui, CH
Rubnitz, JE
Ribeiro, RC
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1411
引用
收藏
页码：327A / 327A
页数：1
相关论文
共 50 条
  • [1] CLADRIBINE(2-CDA) AND CYTARABINE(ARA-C) IS AN EFFECTIVE SALVAGE REGIMEN IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA IN CHILDREN
    Chinnaswamy, Girish
    Prasad, Maya
    Dwivedi, Pankaj
    Patil, Vijay
    Arora, Brijesh
    Banavali, Shripad
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1040 - 1040
  • [2] Cladribine (2-CDA) in combination with Ara-C. Etoposide and G-CSF is effective in secondary or relapsed acute myeloid leukemia (AML).
    Krieger, O
    Kasparu, H
    Girschikofsky, M
    Lutz, D
    BLOOD, 1996, 88 (10) : 3422 - 3422
  • [3] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Richard L Momparler
    Experimental Hematology & Oncology, 2 (1)
  • [4] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Momparler, Richard L.
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2013, 2
  • [5] Circumvention of cytarabine (Ara-C) resistance by 2-chloro-deoxyadenosine (2-CdA) in pediatric acute myeloid (AML) and acute lymphoblastic (ALL) leukemia: An in vitro study.
    Zwaan, CM
    Kaspers, GJL
    Pieters, R
    Huismans, DR
    Van Wering, ER
    Janka-Schaub, GE
    Creutzig, U
    Henze, G
    Veerman, AJP
    BLOOD, 2000, 96 (11) : 307A - 307A
  • [6] 2 chlorodeoxyadenosine (2-CdA) and cytarabine (ara-C) combination is effective and safe in idiopathic hypereosinophilic syndrome (HES).
    Jabbour, E
    Verstovsek, S
    Gandhi, V
    Cortes, J
    Giles, F
    Koller, C
    O'Brien, S
    Plunkett, W
    Garcia-Manero, G
    Jackson, E
    Kantarjian, H
    Andreeff, M
    BLOOD, 2004, 104 (11) : 274B - 274B
  • [7] Irinotecan (CPT-11) and cytarabine (Ara-C) in refractory acute myeloid leukemia (AML).
    Minderman, H
    O'Loughlin, KL
    Thomas, KJ
    Pixley, LA
    Wetzler, M
    Slack, JL
    Baer, MR
    LEUKEMIA, 2001, 15 (03) : 509 - 509
  • [8] CURATIVE EFFECT AND SAFETY OF 2-CDA, ARA-C AND G-CSF COMBINED TREATMENT FOR RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA
    Zhang, Xiaoxiang
    Chen, Ying
    Shou, Lihong
    Yang, Jianghua
    ACTA MEDICA MEDITERRANEA, 2021, 37 (01): : 163 - 167
  • [9] CLOFARABINE IN COMBINATION WITH CYTARABINE (ARA-C) FOR TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN ADULT PATIENTS
    Malato, A.
    Santoro, A.
    Magrin, S.
    Felice, R.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2012, 97 : 502 - 503
  • [10] CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA (AML) REFRACTORY TO ANTHRACYCLINE CYTARABINE (ARA-C) THERAPIES
    KALWINSKY, D
    LOOK, AT
    MIRRO, J
    DAHL, GV
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 193 - 193
12345